ArticleBMC ophthalmology2025
The effect of high-altitude exposure on Vogt-Koyanagi-Harada syndrome: a case report.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundVogt-Koyanagi-Harada (VKH) is a rare and complex autoimmune disease that primarily affects the eyes and the central nervous system. The underlying mechanism of this disease remains unclear, but it is closely related to genetic susceptibility, environmental factors, and abnormal immune responses. This report presents a case of VKH syndrome potentially associated with High-altitude exposure, It highlights that environmental factors may act as a catalyst for the onset of this disease. High altitude can cause retinal lesions from UV radiation and hypoxia, risking visual health. Limited data on VKH in these contexts emphasizes the need for caution among VKH patients traveling to high altitudes. CASE PRESENTATION: A 31-year-old female experienced sudden blurred vision, eye swelling, pain, redness, headache, and tinnitus after a trip to Lhasa, Tibet, where she stayed at high altitude. She had no significant medical history and left the area after symptoms began. Examination showed low visual acuity, normal intraocular pressure, conjunctival injection, and retinal detachment. After diagnosis, she received high-dose steroid therapy, leading to significant improvement in her vision.
conclusionHigh-altitude illness (HAI) arises from hypoxia above 2,500 m, causing symptoms like headaches and fatigue, and significantly impacts VKH syndrome through factors like UV radiation and tissue hypoxia. It may alter immune balance, posing risks for VKH patients in high-altitude areas. In the summary and reflection of this case, we recognized the complexity of VKH and its relationship with environmental factors. Altitude sickness may pose a serious threat to patients with VKH. It is recommended to avoid high-altitude areas (above 2500 m). As it may affect retinal health and cause complications such as vision problems, if it is necessary to go there, a protection plan should be formulated under the assessment of a doctor, and abnormal signs should be monitored. Protecting vision should be the top priority. The uniqueness of this VKH case offers new insights but also has limitations due to the small sample size and lack of a control group; future studies should increase sample size and perform multi-center epidemiological research on high-altitude exposure’s effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.